ライフサイエンスコーパス: fluphenazine

1 s blocked by a dopamine receptor antagonist (fluphenazine).

2 pical application of the dopamine antagonist fluphenazine.

3 privation, amyloid beta peptide (25-35), and fluphenazine.

4 ects on plasma prolactin than risperidone or fluphenazine.

5 ng symptom progression and was comparable to fluphenazine.

6 acy and side effect profile of clozapine and fluphenazine.

7 e effect of the dopamine receptor antagonist fluphenazine (0.1-1.0 mg/kg) was also assessed for compa

8 Fluphenazine (10 or 50 microg/side), infused immediately

9 ly 10 mV in the hyperpolarizing direction by fluphenazine (3 microM for ND7/23 currents and 10 microM

10 y 14 days), which was supplemented with oral fluphenazine (5 mg twice daily) or a placebo when they f

11 The calmodulin inhibitor, fluphenazine (50 microM) inhibited CCh-stimulated PYK-2

12 eline while patients were being treated with fluphenazine and after 12 weeks of double-blind treatmen

13 conventional drugs, such as chlorpromazine, fluphenazine and pimozide, were more toxic than the atyp

14 -week, double-blind crossover trial in which fluphenazine and placebo were administered for 12 weeks

15 he phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antips

16 a or schizoaffective disorder who were given fluphenazine as the first treatment.

17 ribe our electrophysiological examination of fluphenazine at tetrodotoxin-sensitive (TTX-S) and resis

18 demonstrated significant reductions from the fluphenazine baseline in positive symptoms, total sympto

19 ll or Na(V)1.8 currents revealed a prominent fluphenazine block of sodium channel activity.

20 tion, the D1/D2 dopamine receptor antagonist fluphenazine blocked footshock-induced reinstatement whe

21 upenthixol, (+)-butaclamol, haloperidol, and fluphenazine but not SCH23390 or (-)-butaclamol decrease

22 efficacy and tolerability of topiramate and fluphenazine, but more rigorous studies are needed to fu

23 Fluphenazine, but not clozapine, increased metabolic rat

24 R showed a decrease in impulsivity following fluphenazine, but not following either amphetamine or me

25 (ii) Three structurally distinct inhibitors (fluphenazine, calmidazolium and a W-7 analogue) of the C

26 zophrenia were stabilized with a low dose of fluphenazine decanoate (5 to 10 mg every 14 days), which

27 cally stabilized on a maintenance regimen of fluphenazine decanoate for a mean of 16.7 months had the

28 r were randomly assigned to receive 25 mg of fluphenazine decanoate intramuscularly either every 2 we

29 omized to 1 of 3 medication strategies using fluphenazine decanoate under double-blind conditions: co

30 l temporal lobes, whereas clozapine, but not fluphenazine, decreased inferior prefrontal cortex activ

31 We explored the effects of tamoxifen (TAM), fluphenazine (FLU) and estradiol (E2) on ATP levels in H

32 d both radioligands in Acc and IC (30%-70%); fluphenazine had no effect.

33 trols and patients not receiving medication, fluphenazine hydrochloride- and clozapine-treated patien

34 which is comparable to the response rate to fluphenazine in the previous study.

35 butaclamol, haloperidol, chlorpromazine, and fluphenazine inhibited constitutive adenylyl cyclase act

36 Moreover, clozapine and fluphenazine inhibited glucose transport in the rat musc

37 y 2 weeks); or targeted, early intervention (fluphenazine only when symptomatic).

38 Fluphenazine (Prolixin(R)) is a potent phenothiazine-bas

39 Fluphenazine's apparent potency for blocking either ND7/

40 selectively increased MAD scores in WKY and fluphenazine selectively increased MAD scores in SHR.

41 These experiments show fluphenazine to be capable of blocking neuronal sodium c

42 atients compared diazepam with placebo (with fluphenazine treatment for a comparison group).

43 After a baseline fluphenazine treatment period, 29 patients participated

44 ients with schizophrenia received 4 weeks of fluphenazine treatment.

45 When fluphenazine was administered into the nucleus accumbens

46 exacerbation or relapse during this period, fluphenazine was openly withdrawn; participants were the

47 nyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), or fluphenazine were microinjected into rat nucleus accumbe

48 gs, such as sertraline, trifluoperazine, and fluphenazine, were found to be direct inhibitors of the